1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Non-Small Cell Lung Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

DelveInsight’s, “ Non-Small Cell Lung Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global Market therapeutics scenario for Non-Small Cell Lung Cancer.
- A review of the marketed products under prescription for Non-Small Cell Lung Cancer, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Non-Small Cell Lung Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Non-Small Cell Lung Cancer drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Non-Small Cell Lung Cancer drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Non-Small Cell Lung Cancer drugs.
- Coverage of Non-Small Cell Lung Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Non-Small Cell Lung Cancer key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Non-Small Cell Lung Cancer.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to ‘Disease’.
- API intelligence over marketed drugs for Non-Small Cell Lung Cancer and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Non-Small Cell Lung Cancer.
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Non-Small Cell Lung Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information

List of Tables
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Non-Small Cell Lung Cancer Therapeutic Market, US, (Year), 2014
Non-Small Cell Lung Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2014
Non-Small Cell Lung Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Non-Small Cell Lung Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Non-Small Cell Lung Cancer Therapeutic Market, Global Sales (in million USD), 2014
Non-Small Cell Lung Cancer Marketed Drugs, API Manufacturers, Global, 2014
Non-Small Cell Lung Cancer Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Non-Small Cell Lung Cancer, 2014

List of Figures
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Non-Small Cell Lung Cancer Therapeutic Market, US, (Year), 2014
Non-Small Cell Lung Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Non-Small Cell Lung Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Non-Small Cell Lung Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Non-Small Cell Lung Cancer Therapeutic Market, Global Sales (in million USD), 2014
Non-Small Cell Lung Cancer Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Lung Cancer Surgery Market by Procedure, Minimally Invasive, Device, Monitoring, Endoscopic Instrument - Global Forecast to 2021

Lung Cancer Surgery Market by Procedure, Minimally Invasive, Device, Monitoring, Endoscopic Instrument - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The global lung cancer surgery market is segmented based ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • February 2017
    18 pages
  • Cancer  

  • United Kingdom  

View report >

Cancer Statistics in the UK - Forecast

  • February 2017
    6 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Lung Cancer Statistics in Europe

  • February 2017
    5 pages
  • Lung Cancer  

    Therapy  

    Targeted Therap...  

  • Europe  

    World  

    Japan  

View report >

Related Market Segments :

Lung Cancer

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.